• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Clopidogrel monotherapy is superior to aspirin monotherapy for chronic maintenance after percutaneous coronary intervention

byAlice WangandTeddy Guo
July 7, 2021
in Cardiology, Chronic Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Clopidogrel monotherapy reduced long-term rates of all-cause mortality, non-fatal myocardial infarction, and stroke after drug-eluting stent placement compared with aspirin monotherapy.

2. The superiority of clopidogrel was seen for both thrombotic and bleeding endpoints and was consistent across demographic groups.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Patients who receive percutaneous coronary intervention (PCI) with a drug-eluting stent (DES) are recommended to start dual anti-platelet therapy (DAPT) for 6-12 months after intervention and transition to indefinite monotherapy for chronic management. Current guidelines recommend aspirin as the first line option for chronic monotherapy; clopidogrel, a P2Y12 inhibitor, is recommended for those who cannot tolerate aspirin. This prospective, randomized, open-label, multicenter clinical trial (HOST-EXAM) compared the efficacy of clopidogrel monotherapy and aspirin monotherapy for chronic maintenance after PCI with DES. The results of this study demonstrate lower rates of all-cause mortality, as well as thrombotic and bleeding events during the 24-month follow-up period in patients who received clopidogrel monotherapy compared with those who received aspirin monotherapy. These results support the use of clopidogrel for chronic management after PCI to prevent adverse clinical events.

Click to read the study in the Lancet

Relevant Reading: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study 

In-Depth [randomized controlled trial]: This study included 5438 patients who had maintained DAPT following PCI with DES from 37 centers in South Korea. Participants were randomly allocated to clopidogrel (n=2710) and aspirin (n=2728) monotherapy groups in a 1:1 ratio. Patient demographics and baseline characteristics were comparable among groups. Primary endpoint was defined as a composite measure of all-cause death, non-fatal myocardial infarction, stroke, readmission due to acute coronary syndrome, and major bleeding events within the 24-month follow-up window. Secondary endpoints included revascularization procedures, stent thrombosis, and major gastrointestinal complications.

RELATED REPORTS

Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

Empagliflozin use is associated with slower progression of chronic kidney disease

#VisualAbstract: Thromboprophylaxis with aspirin is non-inferior to low-molecular-weight heparin in preventing death for patients with orthopedic trauma

In the follow-up period, 5.7% of patients in the clopidogrel monotherapy event had a primary endpoint event versus 7.7% in the aspirin monotherapy group (hazard ratio [HR] 0.73 [95% CI 0.59-0.90]; p=0.0035). Event rates in all subcomponents of the primary composite endpoint favored clopidogrel monotherapy. Based on Kaplan-Meier curves, differences in event rates emerged approximately 9 months after respective clopidogrel or aspirin monotherapy initiation. The results of this study are limited by potential underreporting of events after study initiation, as event rates were lower than expected, and limited the follow-up time. However, the results of this study support the launch of the 10-year extended HOST-EXAM trial, the results of which could change the current clinical recommendation for chronic maintenance therapy after PCI with DES.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: antiplateletaspirinbleeding eventsbleeding riskcardiologycardiovascularcardiovascular mortalitycardiovascular riskclopidogrelheart attackHeart Attack (Myocardial Infarction)Major Bleeding Eventsmyocardial infarction (MI)P2Y12 inhibitorthromboembolismthrombosisThrombotic Stroke
Previous Post

Standard cytisine treatment for smoking cessation does not demonstrate noninferiority compared to standard varenicline treatment

Next Post

Patients with moderate-severe traumatic brain injury may achieve favourable functional outcomes within 12 months of recovery

RelatedReports

β-blockers linked to improved survival in preserved ejection fraction heart failure
Cardiology

Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

January 27, 2023
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Empagliflozin use is associated with slower progression of chronic kidney disease

January 26, 2023
#VisualAbstract: Thromboprophylaxis with aspirin is non-inferior to low-molecular-weight heparin in preventing death for patients with orthopedic trauma
StudyGraphics

#VisualAbstract: Thromboprophylaxis with aspirin is non-inferior to low-molecular-weight heparin in preventing death for patients with orthopedic trauma

January 24, 2023
Remote patient monitoring did not reduce heart failure readmissions: The BEAT-HF trial
Cardiology

Clinical decision-making strategy improves acute heart failure outcomes

January 12, 2023
Next Post
Combined MRI and NIH stroke scores may predict stroke prognosis

Patients with moderate-severe traumatic brain injury may achieve favourable functional outcomes within 12 months of recovery

Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

Wellness Check: Addictions

#VisualAbstract Ibrutinib may be beneficial in heavily pretreated patients with classic and variant hairy cell leukemia

#VisualAbstract Ibrutinib may be beneficial in heavily pretreated patients with classic and variant hairy cell leukemia

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options